Good morning, ladies and gentlemen, and welcome to Kimball Electronics' fourth quarter fiscal 2026 earnings conference call. My name is Sherry, and I will be the facilitator for today's call. All lines have been placed in a listen-only mode to prevent any background noise. After the completion of prepared remarks from Kimball Electronics leadership team, there will be a question-and-answer period. To ask a question, simply press star and the number one on your telephone keypad. Today's call, August 13, 2026, is being recorded. A replay of the call will be available on the investor relations page of Kimball Electronics website. At this time, I would like to turn the call over to Andy Regrut, Vice President, Investor Relations, Strategic Development, and Treasurer. Mr. Regrut, you may begin. Thank you, and good morning, everyone. Welcome to our fourth quarter conference call. With me here today is Ric Phillips, our Chief Executive Officer, and Jana Croom, Chief Financial Officer. We issued a press release yesterday afternoon with our results for the fourth quarter and full fiscal year ended June 30, 2026. To accompany today's call, a presentation has been posted to the investor relations page on our company website. Before we get started, I would like to remind you that we will be making forward-looking statements that involve risk and uncertainty and are subject to our safe harbor provisions as stated in our press release and SEC filings, and that actual results can differ materially from the forward-looking statements. Our commentary today will be focused on adjusted non-GAAP results. Reconciliations of GAAP to non-GAAP amounts are available in our press release. This morning, Ric will start the call with a few opening comments. Jana will review the financial results for the quarter and guidance for fiscal 2027, and Ric will complete our prepared remarks before taking your questions. I will now turn the call over to Ric. Thank you, Andy, and good morning, everyone. I am proud of our results in the fourth quarter and very good finish to fiscal 2026. Sales in Q4 were in line with expectations. Adjusted operating income was better than estimates, and we generated strong cash from operations, which was used to pay down debt to its lowest level in over four years. Our balance sheet continued to strengthen, and we are actively leveraging it to make strategic investments in growth in the medical CDMO space, such as the build-out of our new medical facility in Indianapolis and the acquisition of Helvoet Polymer Technologies. Our guidance for fiscal 2027 is highlighted by organic sales growth and the accretive impact from Helvoet. We are expecting medical to continue to outpace the other two verticals and represent more than one-third of total company sales in the fiscal year, which is in line with our objective to balance the portfolio across the markets we serve. Turning now to the fourth quarter, net sales for the company were $372 million, a 2% decline compared to Q4 last year, but a 5% sequential increase with all three vertical markets posting gains over Q3. Geographically, sales in the fourth quarter were more evenly distributed around the world versus prior periods, with approximately 40% in North America and 30% in both Asia and Europe. Once again this quarter, our medical business was the headliner, growing both year-over-year and sequentially, and completing a fiscal year where the growth occurred in all four quarters and the total exceeded 10% versus a normalized fiscal 2025 when adjusting for the consigned inventory sale last year. In Q4, medical sales were $109 million, a 1% increase compared to the same period a year ago, and 29% of the total company. Approximately 30% of these sales occurred in both Asia and Europe, with the same year-over-year increases in each region. North America was down mid-single digits, which is below our run rate for most of the fiscal year. This apparent slowdown in the growth trajectory is more of a function of the comparison from a year ago than production this year. In the fourth quarter of fiscal 2025, we were supporting our customers with inventory builds for facility closures and transfers of work. Both were one-time events. From a product category perspective, the growth was driven by demand for surgical devices, in vitro diagnostics, patient monitoring, and drug delivery. Next is automotive with net sales in Q4 of $170 million, down 3% compared to the same period last year and 46% of the total. Our business in the fourth quarter was roughly divided a third, a third, and a third between North America, Asia, and Europe, with Poland and Romania reporting mid-single-digit increases as a result of new steering and braking programs. China was up low single digits and North America was down, driven largely by lower EV demand offsetting these increases. Steering programs continue to be the largest concentration of work, accounting for approximately 70% of total automotive sales for us. For the full year, our automotive business was down 7% year-over-year, so successive 3% declines in the back half of fiscal 2026 suggest a stabilizing trend in this vertical. Finally, sales in industrial totaled $93 million, a 5% decrease compared to Q4 last year and 25% of the total company. Once again, this quarter, our industrial business was heavily concentrated in North America, where the majority of the decline occurred from lower demand for HVAC systems. This was partially offset by higher sales of smart meters in Europe, which continue to recover from prior year declines. I'll now turn the call over to Jana for more detail on our financial results and guidance for fiscal 2027. Jana? Thank you and good morning, everyone. As Ric highlighted, net sales in the fourth quarter were $371.6 million, a 2% decrease year-over-year. Foreign exchange had a 1% favorable impact on consolidated sales in Q4. The gross margin rate in the fourth quarter was 8.9%, a 90 basis point improvement compared to 8% in Q4 of fiscal 2025, with the increase resulting from favorable mix, partially offset by incremental costs associated with the ramp-up of our medical CDMO facility in Indianapolis. Adjusted selling and administrative expenses in the fourth quarter were $14.8 million, a $4 million increase year-over-year, with higher expense from investments for future growth initiatives, including personnel costs and IT infrastructure. When measured as a percentage of sales, the rate was 4% this year compared to 2.8% in the same period last year. Adjusted operating income in Q4 was $18.1 million, or 4.9% of net sales, which compares to last year's adjusted result of $19.6 million, or 5.2% of net sales. Other income and expense was expense of $2.6 million compared to $3.8 million of expense last year. Once again, this quarter, interest expense drove the decrease, down nearly 30% year-over-year as a result of a combination of lower average debt levels and lower borrowing rates. The effective tax rate in Q4 was 67.8%, compared to 48.3% last year, with this year's rate adversely impacted by the resolution of two longstanding dividend withholding matters with tax authorities at international locations. We ended the fiscal year with an effective tax rate of 47.5%, and we're expecting the rate in fiscal 2027 to be in the low 30s. Net income in the fourth quarter was $8.5 million, or $0.35 per diluted share. The adjusted result was skewed by the tax rate, with Q4 posting a loss of $163,000, or a minus $0.01 per diluted share. Turning now to the balance sheet. Cash and cash equivalents at June 30, 2026, were $88.9 million. Cash generated by operating activities in the quarter was a robust $42.4 million, our 10th consecutive quarter of positive cash. Cash conversion days were 82, an eight-day improvement compared to last quarter and three days better than the fourth quarter of fiscal 2025. This is our best CCD in 17 quarters, with all components posting good results, with DSO accounting for the most significant improvement versus prior periods. Inventory ended the quarter at $271.9 million, down slightly, that is $1.4 million, compared to Q3, and $1.6 million lower than a year ago. Capital expenditures in Q4 were $8.5 million. Much of the spend, once again this quarter, on leasehold improvements in the new facility in Indianapolis, plus investments to support new programs in Europe. For the full year, we invested $51.7 million in CapEx, which was in line with our estimates. Borrowings at June 30, 2026, were $116.6 million, representing our lowest level in over four years and a decrease of $46.4 million from the third quarter and down $30.9 million or 21% from a year ago. Short-term liquidity available represented as cash and cash equivalents, plus the unused portion of our credit facilities totaled $411.3 million at the end of the fourth quarter. As a reminder, the acquisition of Helvoet occurred on July 1st, the beginning of fiscal 2027. So the financing activities on that transaction are not reflected in the June 30th balances. We invested $2.1 million in Q4 to repurchase 83,000 shares. Since October 2015, under our board-authorized share repurchase program, a total of $115.6 million has been returned to our share owners by purchasing 7.1 million shares of common stock. In May, our board of directors unanimously increased the share repurchase program by $20 million. We now have $24.4 million available on the program. As we expected, fiscal 2026 was a year of transition, and I am impressed with our team's resilience and ability to deliver results in a challenging environment. We ended the fiscal year with net sales totaling $1.431 billion, with medical up over 10% after normalizing last year for the consigned inventory sale. Adjusted operating income was $65.7 million or 4.6% of net sales. Cash generated from operating activities was $72.3 million, and we invested $11.9 million to repurchase 447,000 shares of common stock. As a CFO who takes great pride in the condition of our balance sheet, we exited the fiscal year in a position of strength with plenty of dry powder in the form of borrowing capacity and available cash to strategically invest. As Ric highlighted, our guidance for fiscal 2027 projects a return to growth, and we will be leveraging our balance sheet to support those efforts. Net sales in fiscal 2027 are expected to be in the range of $1.535 billion- $1.56 billion, a 7%-9% increase compared to fiscal 2026, with organic sales growth of 3%-5% and revenue from Helvoet of $60 million. From a vertical market perspective, organic growth in medical is expected in the high single to low double-digit range, industrial in line with the company average, and automotive will likely be flattish for the year. Revenue should be fairly evenly distributed over the fiscal year. Adjusted operating income is estimated to be 4.4%-4.7% of net sales, and capital expenditures are expected to be in the range of $50 million- $60 million. For FY 2027, the dilutive impact of the ramp of our new facility in Indianapolis is roughly offset by the accretive benefit from our acquisition of Helvoet. We expect this combination of assets to drive significant revenue synergies as we execute our CDMO strategy over time. This outlook reflects the efforts and contributions from all areas of the company, and I am grateful for the collaboration and our return to profitable growth. I'll now turn the call back over to Ric. Thanks, Jana. Before we open the lines for questions, I'd like to share a few thoughts in closing. We are thrilled to see our base business stabilize and a return to organic sales growth, which, as Jana highlighted, will be led by our medical vertical. I noted in my opening comments, our guidance implies medical will approach 35% of the total company in fiscal 2027. Helvoet, the newest member of the Kimball family, is an important contributor. Since the deal announcement in early July, the integration efforts have gone very well, with our number one priority focused on unlocking top-line synergies. Customer interest around the acquisition has been strong, with many customers wanting more information about Helvoet operations in Tilburg and Pune, as well as new requests to tour our facility in Indianapolis, which we welcome as the team there continues to make good progress moving out of the existing campus. Production equipment is now being installed in the new facility, and the qualification of certain manufacturing processes is expected to start in the fall. If all goes according to plan, early production will commence at the end of this calendar year, and the move will be completed in the next 18 months. The addition of Helvoet has given us reason to reconsider how we talk about our medical business, in particular, the co-development work that both organizations do. You may have noticed that we're now incorporating the letter D in our reference to the medical CDMO business. This is reflective of our go-to-market strategy as a full-service provider in Kimball Solutions and will be used going forward. Looking ahead, we continue to evaluate strategic opportunities that could accelerate the expansion of this business, including the lift and shift of assets. As to this strategy, with expertise in precision manufacturing and automation, exposure to highly attractive medical end markets, a presence or expanded presence in a new geography, and a well-run operation with an excellent management team. We believe this strategy will be powerful in driving value creation. Our strategic journey continues to build, and so does my excitement for the future of the company. Operator, we would now like to open the lines for questions. Thank you. Ladies and gentlemen, analysts may ask questions at this time by simply pressing star one on your dial pad. You may remove yourself from the queue by pressing star two on the dial pad. We ask that if you are using a speakerphone, please pick up your handset before asking your question. One moment please for our first question. Our first question is from Brett Fishman with KeyBanc Capital Markets. Please proceed. Hey, guys. Good morning. Thank you so much for taking the questions and good to be on the call today. Just wanted to start off by asking if you could provide a little bit more color on what you saw in the medical segment this quarter, particularly in Asia and Europe, which seemed a little bit stronger. And then it sounded like North America, the biggest impact was comps, but if there's anything else to call out in that geography as well. No, I think with that adjustment, Brett, and thanks for joining the call. Good to have you. It really was a continuation of the trend that we've been seeing throughout the year. As you know, Helvoet will now be included in the results, and of course, it wasn't at all in the prior year with the July 1 close. We saw a pretty consistent double-digit increase over the course of each of the quarters. Again, with that adjustment that you mentioned, Q4 looked pretty similar. Yeah. To give you some technical color, in Q4 of 2025, we had two one-time builds for customers. One was related to a transfer of work, and one was related to a facility closure where they needed to build up inventory in support of that. If you adjust for those things, a normalized quarter-over-quarter FY 2026, FY 2025 is closer to 10%. All right, great. Then maybe just following up on that, it sounds like a key part of the return to positive organic growth in FY 2027, is continued performance in the medical segment with high single digit to low double digit organic growth expected. I was hoping you could just walk through the key drivers and components of that level of growth expected in medical, particularly how much you think could come from the early ramp of the new facility in Indy, or if there's any other incremental contributors compared to FY 2026. Sure. Brett, we're really pleased as we look across the product categories within medical and look at our expectations for the coming year, we see growth in most categories. Respiratory care, surgical devices, in vitro diagnostics, imaging, drug delivery. We're really pleased to see that. I think the Indy impact is definitely going to take time. As you heard on the call, if all goes according to plan, we'll begin to see production by the end of the calendar year. That's going to start with production that is currently taking place in the facility in Indianapolis that we're going to close. That would be transfer rather than incremental growth. What I'd say is, and we can talk more about this, we're really encouraged, and obviously this acquisition just closed as you know, July 1st. The opportunities that we're talking about in terms of synergies are multiple. Helvoet was looking for U.S. footprint anyway, independent of the transaction because of demand from their customers for U.S. footprint for what they do, which they'll now have. We have customers that want footprint in Europe and India, that we didn't necessarily have specifically for those technologies. We're working together to collaborate on scaled larger programs that bring forth the capabilities of both companies. I wouldn't expect you'll see a big impact in 2027 from Indianapolis just because new programs take time to ramp. We may have some good opportunities with lift and shift programs that are already in market that we could move there, but those will take some time as well. It's really a more broad-based improvement, kind of building on the momentum that we saw this year. All right. Super helpful. Last question from me is just on the inorganic contribution. I believe when you announced the deal, I think Helvoet had revenue of around $56 million in calendar year 2025. It just seems like the outlook for inorganic revenue might be a little bit lower than the normalized growth rate for that asset. Just curious if there's any transition impact that you're assuming for year one or any other near-term headwinds that may be impacting the speed of growth for Helvoet. Thank you so much. Hey, Brett. Great question. There are really two impacts. One is actually FX, and the FX translation from the INR and the EUR on the U.S. dollar. That's going to be an impact for our fiscal year. It's not really a transition impact because we've been really, really thoughtful about not interrupting what they've got going on in terms of sales and actually trying to unlock opportunity there in terms of cross-selling opportunities geographically. So, it's much more just business as usual and looking for revenue synergies, but there will be some currency impact. Going from $56 million- $60 million-ish, still 8% top line growth in that range feels pretty good. All right, great. Thank you so much. Our next question is from Mike Crawford with B. Riley Securities. Please proceed. Thank you. Just so we get this into the transcript, what was your EBITDA and EBITDA margin in the fourth quarter? Hey, Mike. The answer for the question. Hold on and I will get that. Got here right in front of me. I apologize. Was it $27.2 million and 7.3%, Jana? It is $28.2 million and yes, 7.6%. Oh, okay. It is in the press release, and we put it in for the first time specifically for you, Mike. It is in the press release. It is hidden in the press release somewhere. Okay. I need to look more closely. I think Ric, you said that the drag from Indianapolis ramp in the current fiscal year is going to be offset by Helvoet. Does that mean that there is only a $5 million drag from ramp up in Indianapolis? You can't necessarily correlate on a revenue dollar for dollar basis. The drag from Indianapolis is probably closer to $6.5 million-$7 million all in. Okay. And would it be fair to assume that there's really almost no drag in the next fiscal year? No. Think of it this way. You've got all of the associated depreciation, plant cost, just all of the things associated, utility expense, et cetera, for a facility that's empty. It's not that there won't be a drag in FY 2028, it's that eventually it will produce enough revenue to overcome the drag. Wait, so are you saying the 18 months isn't from. That's from when you actually start production? We opened the building in February. We are bearing all of the costs associated with that facility, but it is not producing revenue. All of the revenue is at the existing campus. It will start producing revenue. It will open for production in the fourth quarter of the calendar year, our second quarter fiscal year. Then, we will be putting business in it, and it will start to ramp, and it will be able to cover the incremental cost. Okay. Just to clarify, it is 18 months to ramp, not from February, but from December. Roughly, yes. For new programs. For new programs. Yeah. Not lift and shift. Okay. Correct. Not lift and shift. Yeah. Given that your leverage is now 1x-ish EBITDA, is there a best capital structure to run a consistent business like this with perhaps more leverage? If so, what are your capital allocation priorities then, or deployment priorities? Yeah. That's a really great question and something we've been burning a lot of calories on. Somewhere between 1.5 and two times feels good for our business. But you need to keep your balance sheet strong enough that when incremental growth opportunities that are inorganic present themselves, you've got the dry powder to act. You're going to see the cost of the acquisition show up on our balance sheet in Q1. We're going to be actively utilizing our operating cash flow and global cash repatriation options to pay that down so that we can continue to have dry powder should another inorganic opportunity present itself. Plus, we've got $50 million of organic CapEx needs that we need to deploy. We do plan on continuing our share repurchase program at the rate that it's been at for the past few fiscal years. We don't plan on stopping that. We think share repurchase, particularly where our stock price is right now, is also a very compelling opportunity. We plan on doing. It really is sort of a do it all strategy. Share repurchase, yes. Investment in the organic business, yes. But maintaining the dry powder so that we can take advantage of inorganic opportunities. We could take the leverage ratio actually over three times that EBITDA. Obviously, that would be short-lived, and we would have to work aggressively to pay it down. But for the right inorganic opportunity in the short run, would we be willing to do that? Probably. Great. Well, thank you very much. Our next question is from Derek Soderberg with Cantor Fitzgerald. Please proceed. Yeah. Hey, everyone. Thanks for taking the questions. So it looks like automotive sales ended up being down this fiscal year and sort of flattish next year. It sounds like European braking growth is sort of offsetting some of the North America stuff. I guess I was wondering if you just kind of detail your thoughts on that segment sort of turning positive. I know there's individual aspects of the automotive piece by region and braking and steering. I was just wondering if you can maybe comment on when you think that's going to turn positive, kind of the puts and takes between the regions and segments. Just any sort of additional detail on the automotive segment for us to think about. Sure. And Derek, thanks for joining the call. I think we're encouraged to see the stabilizing. The decline is really, as I mentioned earlier on the call, has been driven by low demand for EV programs that we won. It's not programs that we lost, it's just programs that have underperformed in terms of the volumes that we originally anticipated. So we'll see how that continues to evolve with regulations and incentives and so on over time. Don't know how to predict that one. But yes, Europe is strong and these are fairly new programs that will continue to ramp. So we feel really good about where that's at. China is very competitive. Our business has performed pretty well there over a good period of time. But the local Chinese competitors are tough. I'd say our relationships remain as strong as they've ever been. We continue to win the next gen programs, which is really important to us. So, stabilization and an eventual return to growth, market-driven there appears ahead of us and we're going to stay close to those customers and hopefully see some of that demand come back, which it looks like it is overall. Got it. Appreciate the detail there. Jana, congrats on the Cash Conversion Cycle. Really has been trending in the right direction for some time here. I was wondering if that sort of 82-day conversion days, is that sustainable as you guys sort of see growth accelerate here both on an organic and inorganic basis? Any additional thoughts there would be great. Thanks. Yeah, thank you. 82 days was hard-fought, and so it also gives me an opportunity to touch on what we're seeing in the business now, which is we're getting back to an environment where there's some inventory disruption in the supply chain and golden screw type events. Customers are wanting us to carry more inventory. The turns of certain things as we're waiting for that one golden screw is slowing. I'm anticipating that there is going to be some pressure in working capital generally in FY 2027. We've taken that into consideration as we're thinking about the guide for next year and the impact that it's going to have on the balance sheet, and we're managing through it with our customers, but we're already seeing the impact. So if it rose a couple of days in FY 2027. Let me say that differently. We are planning for it to rise a few days in FY 2027. Got it. Appreciate it. Thank you. Our next question is from Max Milius with Lake Street Capital Markets. Please proceed. Hey, guys. Thanks for taking my questions. Just a few questions around the model. I mean, 8.9% on the gross margin, really strong quarter. Obviously, that was impacted by favorable mix. Just curious to know what you are sort of expecting for 2027. Should we be looking for gross margins kind of north of that 8% mark just with the increased focus on the medical side of the business? Thanks. Yeah. Our S&A is sort of trending in that 4% range again. If you consider the midpoint of the guide that we put out being like, call it 4.5-ish, you would need a gross margin in the range of 8.5% for that math to work. That's awesome. I think I heard on the call you are sort of expecting a balanced revenue quarter by quarter throughout the remainder of next year. Is that correct? Yes. That is important because sometimes it is skewed, right? First quarter is really heavy or fourth quarter is really heavy. This year, it just so happens that the way that the forecast is shaking out right now, the quarters are going to be pretty even. Okay. That is it for me. Thanks, guys. Thanks, Max. Thanks, Max. As a reminder, it is star one on your telephone keypad if you would like to ask a question. Our next question comes from Anja Soderstrom with Sidoti & Company. Please proceed. Good morning. This is Alex on for Anja. Thanks for taking questions. Jana, I know you touched on FX and it was a modest tailwind in 2026. What euro assumptions, I am just curious, underpin the 2027 guide now that Helvoet adds euro-denominated revenue? Yeah, 1.14. Sit in brain and engraved in my brain. Very good. Thank you for sharing. I know we have touched on some of the Helvoet contributions for the next year. I am curious what the improved balance sheet and recognizing obviously June 30th figures are pre-Helvoet, how you are thinking about capital allocation priorities on a pro forma basis, and is there a leverage level you are managing towards? Yeah. Somewhere in the 1.5 range feels good. We do not want to be under-leveraged. We do not want to be over-leveraged. As I said, the key is supporting the organic growth of the business and the needs there, but also having enough dry powder that should an inorganic opportunity pop up that was attractive to us, we could use our balance sheet to take advantage of it. It is really walking that line of investing in the base business, which I will remind everyone is still the overwhelming portion of Kimball, and supporting the growth opportunities that we have there, but also dry powder for other tuck-in acquisitions that were going to be force multipliers for the CDMO strategy. I would also add, though, that we just closed on this acquisition July 1. We need to absorb it, integrate it, get the revenue synergies, the top-line synergies out of it. It is also not likely that we would make another acquisition in this fiscal year. We had said that we would want to be serial acquirers in terms of our opportunity set, but we need to give this one time to work before we start chewing on the next one. Helpful context. Thank you. Last one from us. I am curious if there have been any surprises, good or bad, post the Helvoet acquisition, customer retention, integration pace, go to market, anything that is tracking differently, good or bad, than what you underwrote? Oh, great question. In any acquisition, there are things that you are going to learn. I would say, on balance, really positive. The customer conversations, they ask some good questions. Are you going to keep the footprint that Helvoet has today, for example? Yes, we are. I think those all went really well. We anticipate keeping those customers. I think probably the integration process itself is going as expected. Really encouraged. All the leaders are engaged. All the functions are engaged. Facilities are talking to each other. We have a master integration plan that we are on track for. The process itself feels really good, but it is as we expected. I would not say any big changes there. If anything, the top-line synergy opportunities, which are very much still taking shape, have been really encouraging. We are so early, when exactly are they going to happen, and where exactly will they be located, and how big will they be, those are the things that we are working on. The teams across both organizations are talking every single week at least, about a pretty impressive list of potential synergy opportunities leveraging the combined footprint. Also, one of the areas of capital, these are not huge numbers yet, but there were some things with customers that Helvoet had identified that needed to be funded in order to make that opportunity happen, and we are eager to invest in those and have already identified and started to move forward in those capital processes, which are great returns for us. That is contemplated in our CapEx guide. Glad to hear, and thanks again for taking our questions. Yep. There are no further questions at this time. Ladies and gentlemen, thank you for your participation. This does conclude today's teleconference. A replay of the call will be available on the investor relations page of Kimball Electronics' website, or by dialing 877-660-6853. ID number is 13761725. Please disconnect your lines and have a wonderful day.